Form 4: Pfizer CEO Albert Bourla Modifies Stock Appreciation Rights
SEC Form 4
Pfizer's CEO, Albert Bourla, modified his stock appreciation rights (TSRUs) to extend the vesting and settlement dates by two years, according to a recent SEC filing.
Summary
- Albert Bourla, Pfizer's Chairman and CEO, has modified his stock appreciation rights (TSRUs) through a one-time offer by the company.
- The modification extends the vesting and settlement dates of certain outstanding TSRUs by two years.
- The grant price and the number of shares underlying the modified TSRUs remain unchanged.
- Bourla also acquired 18 phantom stock units pursuant to the Pfizer Supplemental Savings Plan, which will be settled in cash upon separation from service.
- The filing details changes in beneficial ownership related to these transactions.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing executive compensation adjustments, with no inherent positive or negative sentiment.
Industry Context
Executive compensation and stock ownership are common practices in publicly traded companies like Pfizer to align management's interests with those of shareholders. Modifications to equity awards, such as extending vesting periods, can be used to incentivize long-term performance.
Comparison to Industry Standards
- Stock appreciation rights are a common form of executive compensation, used by companies like Johnson & Johnson, Merck, and AbbVie.
- The terms and conditions of these awards, including vesting schedules and modification options, vary widely across companies and are often benchmarked against industry peers.
- The Pfizer Supplemental Savings Plan is similar to deferred compensation plans offered by other large corporations, allowing employees to save and invest pre-tax dollars.
Stakeholder Impact
- The modification of stock appreciation rights could incentivize management to focus on long-term shareholder value.
- The Pfizer Supplemental Savings Plan provides employees with a tax-advantaged way to save for retirement.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Pfizer filed a Tender Offer Statement on Schedule TO with the SEC regarding the Modification Offer. |
| 09/12/2024 | Date of transaction involving Stock Appreciation Rights. |
| 09/13/2024 | Date of transaction involving Phantom Stock Units. |
| 09/16/2024 | Date of the SEC filing. |
| 02/23/2027 | Original expiration date for some Stock Appreciation Rights. |
| 02/23/2028 | Original expiration date for some Stock Appreciation Rights. |
| 02/24/2029 | Modified expiration date for some Stock Appreciation Rights. |
| 02/23/2030 | Modified expiration date for some Stock Appreciation Rights. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.